ClinicalTrials.gg

Program

flonoltinib

Also written as “Flonoltinib 75mg”, “Flonoltinib 100mg” and “flonoltinib 25mg”.

Its studies are mostly in Myeloproliferative Disorders · Polycythemia Vera, led by 2 companies.

Furthest: phase 3, since Dec 19, 20257 company-led studies, 4 open or runningNext primary completion: Dec 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chengdu Zenitar Biomedical Technology64 open or runningphase 3since Dec 19, 2025Nov 29, 2021Dec 30, 2026phase 1 · NCT07768111
Guizhou Bailing Group Pharmaceutical10 open or runningphase 1since Aug 12, 2021Aug 12, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2021First study: phase 1 study in Myeloproliferative DisordersNew to Guizhou Bailing Group PharmaceuticalGuizhou Bailing Group Pharmaceutical · NCT05115344
  2. Nov 29, 2021Chengdu Zenitar Biomedical Technology's first study: phase 2 study in Myeloproliferative DisordersNew to Chengdu Zenitar Biomedical TechnologyChengdu Zenitar Biomedical Technology · NCT05153343 · 31 enrolled · China
  3. Jun 7, 2024Phase 2 study in MF,PMF,PPV-MF,PET-MFChengdu Zenitar Biomedical Technology · NCT06457425 · 75 enrolled · China
  4. Sep 24, 2025Phase 2 study in Polycythemia VeraChengdu Zenitar Biomedical Technology · NCT07232290 · 60 planned · China
  5. Dec 19, 2025Phase 3 study in MFPhase 3 reachedChengdu Zenitar Biomedical Technology · NCT07317700 · 105 planned · China
  6. May 12, 2026Phase 1 study in MBChengdu Zenitar Biomedical Technology · NCT07612306 · 6 enrolled · China
  7. Aug 5, 2026Phase 1 study in Drug Interaction ResearchChengdu Zenitar Biomedical Technology · NCT07768111 · 40 planned · China

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Drug Interaction ResearchChengdu Zenitar Biomedical Technology · NCT07768111
  2. Jul 30, 2027Primary completion: phase 2 study in Polycythemia VeraChengdu Zenitar Biomedical Technology · NCT07232290
  3. Dec 30, 2027Primary completion: phase 3 study in MFChengdu Zenitar Biomedical Technology · NCT07317700

TargetBeta

“Flonoltinib Maleate (FM), a triple target inhibitor of JAK2/FLT3/CDK6, has the potential to inhibit JAK2 signaling pathway activity and treat bone marrow proliferative tumors.”study text, by rule · the study

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07768111Drug Interaction Research · China1Not yet recruitingChengdu Zenitar Biomedical TechnologyDec 30, 202640
NCT07612306MB · China1CompletedChengdu Zenitar Biomedical TechnologyJul 25, 20266
NCT07317700MF · China3RecruitingChengdu Zenitar Biomedical TechnologyDec 30, 2027105
NCT07232290Polycythemia Vera · China2RecruitingChengdu Zenitar Biomedical TechnologyJul 30, 202760
NCT06457425MF,PMF,PPV-MF,PET-MF · China2Active, not recruitingChengdu Zenitar Biomedical TechnologyNov 26, 202575
NCT05153343Myeloproliferative Disorders · China2CompletedChengdu Zenitar Biomedical TechnologyNov 29, 202331
NCT05115344Myeloproliferative Disorders1WithdrawnGuizhou Bailing Group PharmaceuticalDec 29, 20220

How it is read

Names in the registry

  • “Flonoltinib 75mg”, 3 entries
  • “Flonoltinib 100mg”, 2 entries
  • “flonoltinib 25mg”, 2 entries
  • “flonoltinib 50mg”, 2 entries
  • “flonoltinib 100mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.